QuidelOrtho Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Brian Blaser

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.2yrs
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Brian Blaser (59 yo)

less than a year

Mandato

Mr. Brian J. Blaser serves as CEO & President at QuidelOrtho Corporation since May 06, 2024 & serves as it's Director since May 15, 2024. He served as an Independent Director at Quanterix Corporation since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Busky	Chief Financial Officer	2.5yrs	US$2.94m	0.018% € 410.0k
Robert Bujarski	Executive VP & COO	4.2yrs	US$3.41m	0.067% € 1.5m
Werner Kroll	Executive Officer	10.5yrs	US$2.03m	0.054% € 1.2m
Michael Iskra	Executive VP & Chief Commercial Officer	less than a year	US$3.32m	0.025% € 572.1k
Brian Blaser	President	less than a year	Nessun dato	Nessun dato
Jonathan Siegrist	Executive VP of Research & Development and CTO	less than a year	Nessun dato	Nessun dato
Juliet Cunningham	Vice President of Investor Relations	1.2yrs	Nessun dato	Nessun dato
Michelle Hodges	Senior VP	3.9yrs	US$3.55m	0.025% € 567.5k
Ronald Bowman	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
William Ferenczy	Point of Care Business Unit Leader	no data	Nessun dato	Nessun dato
Tamara Ranalli	Molecular Diagnostics Business Unit Leader	no data	Nessun dato	Nessun dato

1.2yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di QL1A non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian Blaser	President	less than a year	Nessun dato	Nessun dato
Ann Rhoads	Independent Director	4.3yrs	US$314.47k	0.012% € 279.5k
Kenneth Widder	Independent Director	10yrs	US$320.47k	0.042% € 978.4k
Kenneth Buechler	Independent Non-Executive Chairman	17yrs	US$411.50k	0.13% € 3.0m
Edward Michael	Independent Director	5.9yrs	US$326.94k	0.023% € 539.7k
Mary Polan	Independent Director	31.8yrs	US$300.95k	0.035% € 807.8k
Evelyn Dilsaver	Independent Director	2.5yrs	US$286.95k	0.0077% € 179.1k
Matthew Strobeck	Independent Director	6.6yrs	US$280.00k	0.044% € 1.0m
Robert Schmidt	Independent Director	2.5yrs	US$70.00k	Nessun dato
Joseph Wilkins	Independent Director	3.8yrs	US$280.00k	0.0098% € 226.1k
James Prutow	Independent Director	less than a year	US$110.83k	0.0023% € 52.2k

4.3yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di QL1A sono considerati esperti (durata media dell'incarico 4.3 anni).

QuidelOrtho Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.19 loss in 3Q 2023)

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation to Report Q3, 2024 Results on Nov 07, 2024

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400

QuidelOrtho Corporation to Report Q2, 2024 Results on Jul 31, 2024

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$25.50 loss per share (vs US$0.73 profit in 1Q 2023)

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Full year 2023 earnings released: US$0.15 loss per share (vs US$9.66 profit in FY 2022)

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

New minor risk - Share price stability

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$0.15 loss per share (vs US$9.66 profit in FY 2022)

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

QuidelOrtho Corporation Announces Board Changes

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.29 profit in 3Q 2022)

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.80 loss per share (vs US$0.37 profit in 2Q 2022)

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.73 (vs US$11.46 in 1Q 2022)

Full year 2022 earnings released: EPS: US$9.66 (vs US$16.74 in FY 2021)

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$5.17 in 3Q 2021)

QuidelOrtho Corporation to Report Q3, 2022 Results on Nov 02, 2022

QuidelOrtho Corporation (NasdaqGS:QDEL) announces an Equity Buyback for $300 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.37 (vs US$0.46 in 2Q 2021)

QuidelOrtho Corporation to Report Q2, 2022 Results on Aug 04, 2022

Investor sentiment improved over the past week

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from Russell 2500 Growth Index

High number of new directors

High number of new directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media